Gendius technology for diabetes risk prediction launched in the GCC through new AstraZeneca patient support app, Health Gate
A new digital health platform which provides enhanced support to diabetes patients in the Gulf Cooperation Council (GCC) region has launched through a collaboration between British health technology startup, Gendius, and leading biopharmaceutical company, AstraZeneca.
The Health Gate patient support app is powered by Gendius’ unique, AI-powered Intellin® platform, which analyses patients’ clinical and lifestyle data to forecast their risk of developing diabetes complications, allowing users to track and manage their diabetes on a daily basis. Intellin is the only technology platform that calculates individual risk for developing diabetes complications, and provides clinically-validated guidance on how they can best manage that risk.
In addition to the integrated risk monitoring through Intellin, Health Gate also offers patients a comprehensive diabetes management solution through access to online consultations, e-prescriptions, access to a library of additional resources, and educational materials.
Gendius’ CEO, Rory Cameron, commented, “We are so pleased to have been able to work with the AstraZeneca team to bring this exciting new technology platform to diabetes patients in the GCC countries. Our Intellin AI-driven risk monitoring, in combination with the enhanced patient support and HCP engagement, makes this a really comprehensive remote management solution. We look forward to further close collaboration with the AstraZeneca team in the future to further enhance and expand the platform.”
Enhanced diabetes management is high on the agenda of the GCC countries, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Increased awareness and education about the best ways to manage diabetes and reduce the risk of developing serious complications have been identified as key to addressing the impact of diabetes in the region.
The partnership between Gendius and AstraZeneca was implemented within the framework of AstraZeneca’s Emerging Markets Health Innovation Hubs initiative to create integrated science ecosystems through local bio-hubs across the world. AstraZeneca’s Health Innovation Hubs have fast become vital resources for Emerging Market countries, bridging the gaps in infrastructure while promoting shared working across the International region.